Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent

International Journal of Pharmaceutics

Volumn 320, Issue 1-2, 2006, Pages 157-164

  Malzert Freon A ^a   Vrignaud, S ^a   Saulnier, P ^b   Lisowski, V ^c   Benoit J P ^b   Rault, S ^a  

^a CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

Cytotoxic activity; Interfacial tension measurements; Lipid nanoparticles; Tripentones

Indexed keywords

ANTINEOPLASTIC AGENT; BUFFER; DRUG CARRIER; LABRAFAC; LIPID; NANOPARTICLE; OIL; PHOSPHATE; SOLUTOL HS 15; SURFACTANT; TRIACYLGLYCEROL; TRIPENTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CELL PROLIFERATION; CYTOTOXICITY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; FLOW KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; KINETICS; LIGHT SCATTERING; MOLECULE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PRODUCTIVITY; SUSTAINED RELEASE FORMULATION; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLOIDS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FEASIBILITY STUDIES; INHIBITORY CONCENTRATION 50; MICE; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; PYRROLIZIDINE ALKALOIDS; RHEOLOGY; SOLUBILITY; STEARIC ACIDS; SURFACE TENSION; TIME FACTORS; TRIGLYCERIDES; TUBULIN MODULATORS;

EID: 33746451664     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.04.007     Document Type: Article

References (30)

1. Barnes M.N., Grizzle W.E., Grubbs C.J., and Partridge E.E. Paradigms for primary prevention of ovarian carcinoma CA-cancer. J. Clin. 52 (2002) 216-225
2. Boury F., Ivanova T., Panaiotov I., Proust J.E., Bois A., and Richou J. Dilatational properties of adsorbed poly(d, l-lactide) and bovine serum albumin monolayers at the dichloromethane/water interface. Langmuir 11 (1995) 1636-1644
3. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
4. Cahouet A., Denizot B., Hindré F., Passirani C., Heurtault B., Moreau M., Le Jeune J.J., and Benoît J.P. Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and γ counting. Int. J. Pharm. 242 (2002) 367-371
5. Feng S.-S., and Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 58 (2003) 4087-4114
6. Gref R., Domb A., Quellec P., Blunk T., Müller R.H., Verbavatz J.M., and Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16 (1995) 215-233
7. Heurtault, B., Saulnier, P., Benoît, J.P., Proust, J.E., Pech, B., Richard, J., 2000. Nanocapsules lipidiques, procédé de préparation et utilisation comme médicament. French Patent 0002688000.
8. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoît J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
9. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. Properties of Polyethylene glycol 660 12-hydroxy stearate at the triglycerides/water interface. Int. J. Pharm. 242 (2002) 167-170
10. Heurtault B., Saulnier P., Pech B., Venier-Julienne M.C., Proust J.E., Phan-Tan-Luu R., and Benoît J.P. The influence of lipid nanocapsule composition on their size distribution. Eur. J. Pharm. Sci. 18 (2003) 55-61
11. Hoarau D., Delmas P., David S., Roux E., and Leroux J.C. Novel long-circulating lipid nanocapsules. Pharm. Res. 21 (2004) 1783-1789
12. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M. Cancer statistics CA-cancer. J. Clin. 55 (2005) 10-30
13. Lamprecht A., Bouligand Y., and Benoît J.P. New lipid nanocapsules exhibit sustained release properties for amiodarone. J. Control. Release 84 (2002) 59-68
14. Lamprecht A., Saumet J.L., Roux J., and Benoit J.P. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int. J. Pharm. 278 (2004) 407-414
15. Lisowski, V., 2002. Conception, synthèse, étude physico-chimique et évaluation biologique de "tripentones" à visée anticancéreuse. Ph.D. Thesis. Caen University.
16. Lisowski V., Enguehard C., Lancelot J.C., Caignard D.H., Lambel S., Leonce S., Pierre A., Atassi G., Renard P., and Rault S. Design synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. Bioorg. Med. Chem. Lett. 11 (2001) 2205-2208
17. Lisowski V., Leonce S., Kraus-Berthier L., Sopkova de Oliveira Santos J., Pierre A., Atassi G., Caignard D.H., Renard P., and Rault S. Design, synthesis and evaluation of a novel thienopyrrolizinone as antitubulin agents. J. Med. Chem. 47 (2004) 1448-1464
18. Malzert A., Boury F., Renard D., Robert P., Proust J.E., and Benoit J.P. Influence of some formulation parameters on lysozyme adsorption and on its stability in solution. Int. J. Pharm. 242 (2002) 405-409
19. Malzert A., Boury F., Saulnier P., Benoit J.P., and Proust J.E. Rheological study of lysozyme and PEG2000 at the air-water and dichloromethane-water interfaces under ramp type or sinusoidal perturbations. Langmuir 18 (2002) 10248-10254
20. Maulucci G., De Spirito M., Arcovito G., Boffi F., Castellano A.C., and Briganti G. Particle size distribution in DMPC vesicles solutions undergoing different sonication times. Biophys. J. 88 (2005) 3545-3550
21. Mc Guire W.P., and Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer 89 (2003) 3-8
22. Minkov I., Ivanova T., Panaiotov I., Proust J., and Saulnier P. Reorganization of lipid nanocapsules at air-water interface. I. Kinetics of surface film formation. Colloid Surf. B 45 (2005) 14-23
23. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., Xu X., and Hamilton T.C. Focus on epithelial ovarian cancer. Cancer Cell 5 (2004) 19-24
24. Panaiotov I., Ivanova T., Proust J.E., Boury F., Denizot B., Keough K., and Taneva S. Effect of hydrophobic protein SP-C on structure and dilatational properties of the model monolayers of pulmonary surfactant. Colloid Surf. B 6 (1996) 243-260
25. Pierre A., Krauss-Berthier L., Atassi G., Cros S., Poupon M.F., Lavielle G., Berlion M., and Bizzari J.P. Preclinical antitumor activity of a new vinca alkaloid derivative S12363. Cancer Res. 51 (1991) 2312-2318
26. Rault, S., Enguehard, C., Lancelot, J.C., Robba, M., Atassi, G., Pierre, A., Caignard, D.H., Renard, P., 1998. Nouveaux dérivés de 8H-thieno[2,3-b]pyrrolizine-8-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. European Patent 9809552.
27. Saulnier P., Boury F., Malzert A., Heurtault B., Ivanova T., Cagna A., Panaiotov I., and Proust J.E. Rheological model for the study of dilatational properties of monolayers comportment of dipalmitoylphosphatidylcholine (DPPC) at the dichloromethane (DCM)/water interface under ramp type or sinusoidal perturbations. Langmuir 17 (2001) 8104-8111
28. 2-water pure interface. J. Phys. Chem. B 109 (2005) 3990-3997
29. Vonarbourg A., Saulnier P., Passirani C., and Benoit J.P. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis 26 (2005) 2066-2075
30. Ziller C., Lincet H., Muller C.D., Staedel C., Behr J.-P., and Poulain L. The cyclin-dependent kinase inhibitor p21cip1/waf1 enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett. 212 (2004) 43-52